NEWS | BEAM Alliance

NEWS

Investors Support Phage Therapy; Novel Approach to Solve The Antibiotics Crisis Receives Further Millions

Investors Support Phage Therapy

Novel Approach to Solve The Antibiotics Crisis Receives Further Millions

Vienna (Austria), 27. Juni 2019: Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further €1.5 million in equity investments to support this novel approach to tackle the antibiotics crisis. The additional funding will be used to accelerate three in-house development programs.

Full PR available here